An international consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease has recently been published. The statement is an important starting point to address the many problems we still have with the clinical classification and treatment of fistulising Crohn's disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gecse, K. B. et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut http:/dx.doi.org/10.1136/gutjnl-2013-306709.
Pittet, V. et al. Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Aliment. Pharmacol. Ther. 32, 1007–1016 (2010).
Vermeire, S., Van Assche, G. & Rutgeerts, P. Perianal Crohn's disease: classification and clinical evaluation. Dig. Liver Dis. 39, 959–962 (2007).
Irvine, E. J. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J. Clin. Gastroenterol. 20, 27–32 (1995).
Present, D. H. et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340, 1398–1405 (1999).
Schwartz, D. A. & Herdman, C. R. Review article: The medical treatment of Crohn's perianal fistulas. Aliment. Pharmacol. Ther. 19, 953–967 (2004).
Van Assche, G. et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am. J. Gastroenterol. 98, 332–339 (2003).
Bataille, F. et al. Morphological characterisation of Crohn's disease fistulae. Gut 53, 1314–1321 (2004).
Bataille, F. et al. Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflamm. Bowel Dis. 14, 1514–1527 (2008).
Scharl, M. et al. Interleukin-13 and transforming growth factor β synergise in the pathogenesis of human intestinal fistulae. Gut 62, 63–72 (2013).
Acknowledgements
G.R. acknowledges grant support from the Swiss National foundation (314730_153380 TDAG8, 324730_138291, 310030_138410 and 33CS30_148422, Swiss IBD Cohort study).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G.R. has acted as a consultant to Abbott, Augurix, Calypso, Essex/MSD, FALK, Genentech, Novartis, Roche, Tillotts Pharma, UCB and Vifor Pharma. G.R. has received speaker's honoraria from Abbott, FALK, MSD, Phadia, Tillotts Pharma, UCB and Vifor Pharma, and received educational grants and research grants from Abbott, Ardeypharm, Essex/MSD, FALK, Flamentera AG, Novartis, Roche, Tillotts Pharma, UCB and Zeller.
Rights and permissions
About this article
Cite this article
Rogler, G. Fistulising disease—a problem shared is a problem halved?. Nat Rev Gastroenterol Hepatol 11, 581–583 (2014). https://doi.org/10.1038/nrgastro.2014.142
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.142
This article is cited by
-
Chronisch-entzündliche Darmerkrankungen
coloproctology (2016)